These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

403 related articles for article (PubMed ID: 27595250)

  • 21. How Well Do Stroke Risk Scores Predict Hemorrhage in Patients With Atrial Fibrillation?
    Quinn GR; Singer DE; Chang Y; Go AS; Borowsky LH; Fang MC
    Am J Cardiol; 2016 Sep; 118(5):697-9. PubMed ID: 27394408
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CHA
    D'Souza M; Carlson N; Fosbøl E; Lamberts M; Smedegaard L; Nielsen D; Torp-Pedersen C; Gislason G; Schou M
    Eur J Prev Cardiol; 2018 Apr; 25(6):651-658. PubMed ID: 29482441
    [TBL] [Abstract][Full Text] [Related]  

  • 23. CHA
    Peacock WF; Tamayo S; Patel M; Sicignano N; Hopf KP; Yuan Z
    Ann Emerg Med; 2017 May; 69(5):541-550.e1. PubMed ID: 27913059
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessing the risk of bleeding in patients with atrial fibrillation: the Loire Valley Atrial Fibrillation project.
    Lip GY; Banerjee A; Lagrenade I; Lane DA; Taillandier S; Fauchier L
    Circ Arrhythm Electrophysiol; 2012 Oct; 5(5):941-8. PubMed ID: 22923275
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [2010 European guidelines for antithrombotic therapy in patients with atrial fibrillation and new risk score for the assessment of the risk of bleeding].
    Melon P; Lancellotti P
    Rev Med Liege; 2010 Oct; 65(10):580-2. PubMed ID: 21128364
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Atrial fibrillation and stroke].
    Aamodt AH; Sandset PM; Atar D; Tveit A; Russell D
    Tidsskr Nor Laegeforen; 2013 Aug; 133(14):1453-7. PubMed ID: 23929293
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry.
    Bakhai A; Darius H; De Caterina R; Smart A; Le Heuzey JY; Schilling RJ; Zamorano JL; Shah M; Bramlage P; Kirchhof P
    Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):299-305. PubMed ID: 29474715
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Use of Vitamins K antagonists in non-valvular atrial fibrillation thromboembolic risk prevention in Burkina Faso.
    Yameogo AR; Kologo JK; Mandi G; Kabore HP; Millogo GR; Seghda AA; Samadoulougou AK; Zabsonre P
    Pan Afr Med J; 2016; 24():108. PubMed ID: 27642447
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation.
    Lip GY
    Am J Med; 2011 Feb; 124(2):111-4. PubMed ID: 20887966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Reviewing a clinical decision aid for the selection of anticoagulation treatment in patients with nonvalvular atrial fibrillation: applications in a US managed care health plan database.
    Deitelzweig SB; Jing Y; Swindle JP; Makenbaeva D
    Clin Ther; 2014 Nov; 36(11):1566-1573.e3. PubMed ID: 25438725
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Optimising stroke prevention in patients with atrial fibrillation: application of the GRASP-AF audit tool in a UK general practice cohort.
    Shantsila E; Wolff A; Lip GY; Lane DA
    Br J Gen Pract; 2015 Jan; 65(630):e16-23. PubMed ID: 25548312
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CHA
    Carr BW; Wooster ME; Nemani LA; Severance SE; Hartwell JL
    Am J Emerg Med; 2022 Jan; 51():119-123. PubMed ID: 34735969
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Impact of Baseline Stroke Risk and Bleeding Risk on Warfarin International Normalized Ratio Control in Atrial Fibrillation (from the TREAT-AF Study).
    Hellyer JA; Azarbal F; Than CT; Fan J; Schmitt SK; Yang F; Frayne SM; Phibbs CS; Yong C; Heidenreich PA; Turakhia MP
    Am J Cardiol; 2017 Jan; 119(2):268-274. PubMed ID: 27836133
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predictive value of the CHA2DS2-VASc score in atrial fibrillation patients at high risk for stroke despite oral anticoagulation.
    Jover E; Roldán V; Gallego P; Hernández-Romero D; Valdés M; Vicente V; Lip GY; Marín F
    Rev Esp Cardiol (Engl Ed); 2012 Jul; 65(7):627-33. PubMed ID: 22609214
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.
    Sulzgruber P; Wassmann S; Semb AG; Doehner W; Widimsky P; Gremmel T; Kaski JC; Savarese G; Rosano GMC; Borghi C; Kjeldsen K; Torp-Pedersen C; Schmidt TA; Lewis BS; Drexel H; Tamargo J; Atar D; Agewall S; Niessner A
    Eur Heart J Cardiovasc Pharmacother; 2019 Jul; 5(3):171-180. PubMed ID: 31119266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implications of stroke and bleeding risk scores and comorbidities on episode-based bundled payments for patients with nonvalvular atrial fibrillation.
    Kaatz S; Coleman CI; Bookhart B; Laliberté F; Nelson WW; Brown K; Martin S; Schein J; Lefebvre P
    Curr Med Res Opin; 2018 Feb; 34(2):275-284. PubMed ID: 29164990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic therapy in elderly patients with non-valvular atrial fibrillation: a pilot study.
    Xiang W; Zhang J; Liu M; Liu F; Feng X; Wang Y
    Clin Interv Aging; 2015; 10():515-9. PubMed ID: 25767378
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The impact of risk score (CHADS2 versus CHA2DS2-VASc) on long-term outcomes after atrial fibrillation ablation.
    Jacobs V; May HT; Bair TL; Crandall BG; Cutler M; Day JD; Weiss JP; Osborn JS; Muhlestein JB; Anderson JL; Mallender C; Bunch TJ
    Heart Rhythm; 2015 Apr; 12(4):681-6. PubMed ID: 25546809
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should we recommend oral anticoagulation therapy in patients with atrial fibrillation undergoing coronary artery stenting with a high HAS-BLED bleeding risk score?
    Ruiz-Nodar JM; Marín F; Roldán V; Valencia J; Manzano-Fernández S; Caballero L; Hurtado JA; Sogorb F; Valdés M; Lip GY
    Circ Cardiovasc Interv; 2012 Aug; 5(4):459-66. PubMed ID: 22787018
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Should atrial fibrillation patients with 1 additional risk factor of the CHA2DS2-VASc score (beyond sex) receive oral anticoagulation?
    Chao TF; Liu CJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Tuan TC; Chen TJ; Lip GY; Chen SA
    J Am Coll Cardiol; 2015 Feb; 65(7):635-42. PubMed ID: 25677422
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.